| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | 0.038 | 0.4 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.4 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | -0.022 | 0.4 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.024 | 0.4 |
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.4 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.025 | 0.4 |
| mRNA | ZSTK474 | GDSC1000 | pan-cancer | AAC | 0.023 | 0.4 |